DE69432190D1 - Papamycinderivate - Google Patents

Papamycinderivate

Info

Publication number
DE69432190D1
DE69432190D1 DE69432190T DE69432190T DE69432190D1 DE 69432190 D1 DE69432190 D1 DE 69432190D1 DE 69432190 T DE69432190 T DE 69432190T DE 69432190 T DE69432190 T DE 69432190T DE 69432190 D1 DE69432190 D1 DE 69432190D1
Authority
DE
Germany
Prior art keywords
papamycinderivate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432190T
Other languages
English (en)
Other versions
DE69432190T2 (de
Inventor
Juan Ignacio Luengo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Application granted granted Critical
Publication of DE69432190D1 publication Critical patent/DE69432190D1/de
Publication of DE69432190T2 publication Critical patent/DE69432190T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69432190T 1994-02-23 1994-08-02 Papamycinderivate Expired - Fee Related DE69432190T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/200,265 US5362735A (en) 1994-02-23 1994-02-23 Rapamycin derivatives
PCT/US1994/008726 WO1995022972A1 (en) 1994-02-23 1994-08-02 Rapamycin derivatives

Publications (2)

Publication Number Publication Date
DE69432190D1 true DE69432190D1 (de) 2003-04-03
DE69432190T2 DE69432190T2 (de) 2003-11-27

Family

ID=22740995

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432190T Expired - Fee Related DE69432190T2 (de) 1994-02-23 1994-08-02 Papamycinderivate

Country Status (5)

Country Link
US (1) US5362735A (de)
EP (1) EP0754040B1 (de)
JP (1) JPH10500661A (de)
DE (1) DE69432190T2 (de)
WO (1) WO1995022972A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336499A (en) * 1992-01-10 1994-08-09 Antelman Technologies, Ltd. Molecular crystal device for pharmaceuticals
US6187757B1 (en) * 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
EP0937082A2 (de) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Nicht immunhemmende antifungale rapaloge
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
CA2383451A1 (en) * 1999-08-24 2001-03-01 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU2748701A (en) 1999-10-29 2001-06-06 Kosan Biosciences, Inc. Rapamycin analogs
WO2004014222A2 (en) * 2002-08-12 2004-02-19 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
EP1648454A1 (de) * 2003-07-25 2006-04-26 Wyeth Lyophilisierte formulierung von cci-779
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
JP2011502954A (ja) 2006-12-27 2011-01-27 ザ ジョンズ ホプキンス ユニバーシティー 免疫応答を刺激する組成物および方法
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20080188461A1 (en) * 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
WO2009089549A1 (en) * 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2473523A2 (de) 2009-08-31 2012-07-11 Amplimmune, Inc. Verfahren und zusammensetzungen zur hemmung von transplantatabstossung
CA2772411C (en) * 2009-09-10 2017-08-22 Kominox, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US20110150798A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for increasing cellular far and bleaching skin
CA2822746A1 (en) * 2009-12-21 2011-06-30 Sarah Bacus Compositions and methods for treatment of vitiligo
EP2589383A1 (de) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP-subtypspezifisches Rapamycin-Analogon zur Verwendung bei der Behandlung von Erkrankungen
EP2836234B1 (de) 2012-04-12 2019-06-12 Yale University Vehikel zur kontrollierten abgabe verschiedener pharmazeutischer substanzen
MX2015007846A (es) 2012-12-19 2016-04-28 Amplimmune Inc Anticuerpos anti-b7-h4 humana y sus usos.
EP2997373A1 (de) 2013-05-17 2016-03-23 MedImmune, LLC Rezeptoren für b7-h4
CN105283553B (zh) 2013-06-11 2021-06-25 克隆技术实验室有限公司 蛋白质富集的微泡及其制备和使用方法
ES2957882T3 (es) 2015-09-04 2024-01-29 Univ Yale Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
AU2019265632A1 (en) 2018-05-09 2021-01-07 Yale University Particles for spatiotemporal release of agents
US20210115378A1 (en) 2018-05-09 2021-04-22 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
LT3813946T (lt) 2018-06-15 2024-07-10 Janssen Pharmaceutica Nv Rapamicino analogai ir jų panaudojimas
EP4069223A4 (de) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV Rapamycinanaloga und verwendungen davon
CN116600789A (zh) 2020-06-19 2023-08-15 耶鲁大学 用于诱导耐受性的聚合胆汁酸酯纳米颗粒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives

Also Published As

Publication number Publication date
JPH10500661A (ja) 1998-01-20
EP0754040B1 (de) 2003-02-26
EP0754040A1 (de) 1997-01-22
US5362735A (en) 1994-11-08
WO1995022972A1 (en) 1995-08-31
DE69432190T2 (de) 2003-11-27
EP0754040A4 (de) 1997-07-02

Similar Documents

Publication Publication Date Title
DE59508357D1 (de) Stereomikroscop
ATA166795A (de) Bis-resorcinyltriazine
ATA147195A (de) Alkoxyphenyl-substituierte bisbenzoylphosphinoxide
ATA163695A (de) 2-hydroxyphenyltriazine
DE69432190D1 (de) Papamycinderivate
DE59501347D1 (de) Hydroxyphenylharnstoffe
DE59506964D1 (de) Polyglycerinpolyricinoleate
ATA108995A (de) Differenzdruckakkumulator
DE59508868D1 (de) Dihydrofarnesal
DE59510691D1 (de) Dipolspeiseanordnung
DE69415306D1 (de) Ablenkjoch
DE59503633D1 (de) Zyklonsichter
ATA11894A (de) Stauförderbahn
BR9506519A (pt) Azatrioxaspiroalquenos
DE59507451D1 (de) Cyanoisoxazole
BR7400683U (pt) Odontoportátil
FI1430U1 (fi) Axelspaerr foer fordon
ATE197372T1 (de) Vorteig
BR7401967U (pt) Vassoura-mangueira
FIU940258U0 (fi) Floete
BR7400242U (pt) Tele-comando
BR7400170U (pt) Mouráo
BR7401742U (pt) Sub-capacete
BR9403309A (pt) Choppometro
BR7400062U (pt) Prato-bandeja

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee